Prognoza
Nie mamy danych analityków dla tej spółki.
Dyskusje w społeczności
Nie ma jeszcze dyskusji o tym aktywie.
Rozpocznij dyskusjęWiadomości Przejdź do aktualności
DocMorris raises forecast after 260% rally and improves operating result
The DocMorris share rose by around 260% over twelve months, driven by a markedly improved operating performance. At its capital markets day the company raised its revenue target to about 15% growth, supported by a strong Rx business (over 90% growth in prescription drugs in October) and improved margins. Adjusted EBITDA is expected to be at worst -10m CHF; a small positive was already achieved in the third quarter, and a free-cash-flow break-even is expected for 2027. Investors should note the strong rally and the earlier 200m CHF capital increase. » Więcej na deraktionaer.de
DocMorris raises outlook after strong sales and prescription growth
DocMorris increased sales in the third quarter by 21% to CHF 343m and reached CHF 971m in the first nine months (+14%). The prescription drug business grew in Q3 by 78% to CHF 108m, active customers rose by 1.5m to 13.1m. For 2026 the company now expects sales growth of 12–15% (in local currency) and lowers the expected EBITDA loss to below CHF 10m. The share price jumped about 8% and hit a 52-week high. » Więcej na deraktionaer.de
Apothekerkammer seizes €110,000 from DocMorris following court rulings
The Apothekerkammer Nordrhein carried out enforcement measures in the Netherlands against DocMorris for over €110,000 after the company was said to have breached final German judgments on advertising and discounts. German pharmacists had previously applied for administrative fines and achieved their enforcement in the Netherlands. DocMorris called the measure an enforcement of administrative fines, intends to appeal, and sees no impact on its operations or financial stability. » Więcej na heise.de
Pharmacy chamber seizes €110,000 from DocMorris after breach of German judgments
The Apothekerkammer Nordrhein carried out enforcement measures in the Netherlands for €110,000 after DocMorris was said to have violated final German judgments on advertising and discounts. DocMorris described the action as enforcement of administrative fines, announced it would appeal, and stressed that it has no impact on operations or financial stability. The case is part of the years-long dispute between the online provider based in the Netherlands and German brick-and-mortar pharmacies over competitive conditions and cross-border trade. » Więcej na finanzen.net
DocMorris in the Netherlands seized over unpaid fines
A court in Limburg ruled the seizure of accounts belonging to mail-order pharmacy DocMorris lawful after the Apothekerkammer Nordrhein applied for enforcement over unpaid, final administrative fines from Germany. The fines stem from prohibited price advertising, for which Stuttgart imposed several penalties (including €50,000, €60,000 and €100,000); the chamber says unpaid sums run into the millions. DocMorris can appeal within four weeks; the company did not comment on the proceedings. DocMorris is based in Heerlen and generated about €327.2m in revenue on the German market in Q1 2026 (+11.1%). » Więcej na t-online.de
Historyczne dywidendy Dywidendy
Wszystkie wskaźniki dywidendowe Wszystkie wskaźnikiW 2016 roku DocMorris wypłaciła już 0,46 € dywidend. Ostatnia wypłata nastąpiła w czerwiec 2016.
Dane finansowe
W ostatnim kwartale DocMorris osiągnęła przychody w wysokości 649,14 mln € i zysk netto w wysokości -57,53 mln €
| (EUR) | czerwiec 2026 | YoY |
|---|---|---|
| Przychody | 649,14 mln | - |
| Zysk brutto | 59,51 mln | - |
| Zysk netto | -57,53 mln | - |
| EBITDA | -21,69 mln | - |
Dane fundamentalne
| Wskaźnik | Wartość |
|---|---|
Kapitalizacja rynkowa | 1,01 mld € |
Liczba akcji | 50,49 mln |
Maksimum/minimum z 52 tygodni | 21,19 € - 4,25 € |
| Dywidendy | Nie |
Beta | 1,86 |
C/Z (PE Ratio) | -11,72 |
PEG (PEG Ratio) | -0,12 |
C/WK (PB Ratio) | 2,53 |
C/S (PS Ratio) | 0,79 |
Profil spółki
Zur Rose Group AG prowadzi internetową aptekę oraz działalność hurtową w zakresie produktów medycznych i farmaceutycznych pod markami Zur Rose i DocMorris w Niemczech, Szwajcarii i pozostałej części Europy. Oferuje produkty z zakresu zdrowia konsumenckiego, urody i higieny osobistej. Firma świadczy także usługi zarządzania lekami. Prowadzi stacjonarne sklepy aptekarskie. Spółka sprzedaje swoje produkty bezpośrednio lekarzom, internetowym aptekom wysyłkowym oraz osobom prywatnym. Firma była wcześniej znana jako Zur Rose AG i w maju 2015 roku zmieniła nazwę na Zur Rose Group AG. Zur Rose Group AG została założona w 1993 roku i ma siedzibę we Frauenfeld w Szwajcarii.
| Nazwa | DocMorris |
| CEO | Walter Hess |
| Siedziba | Frauenfeld,
th Szwajcaria |
| Strona internetowa | |
| Sektor | Ochrona zdrowia |
| Branża | Ochrona zdrowia: świadczeniodawcy i usługi |
| Debiut giełdowy | 06.07.2017 |
| Pracownicy | 1454 |
Symbole giełdowe
| Giełda | Symbol |
|---|---|
SIX | ROSE.SW |
Düsseldorf | ZRE.DU |
Frankfurt | ZRE.F |
London | 0RRB.L |
München | ZRE.MU |
Pnk | ZRSEF |
London Stock Exchange | 0RRB.L |
Nse | IITL.NS |
Australian Securities Exchange Ltd | SRX.AX |
Bse | NILA.BO |
Toronto Stock Exchange | EVGN.V |